LISPRO-PH20 COMPONENT RHUPH20
Monocytic Leukemia
Masonic Cancer Center, University of Minnesotaprotein_peptidePhase 1Active
CC
46/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 89/ 100
Competitive context
8 Active assets in the Monocytic Leukemia cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Enasidenib Tian Yi Zhang | Phase 1/2 | CCC |
Cyclophosphamide Masonic Cancer Center, University of Minnesota | Phase 1 | CC |
Fludarabine Masonic Cancer Center, University of Minnesota | Phase 1 | CC |
DARATUMUMAB Masonic Cancer Center, University of Minnesota | Phase 1 | CC |
Mitoxantrone University of Colorado, Denver | Phase 1 | CC |
Azacitidine University of Colorado, Denver | Phase 1 | CC |
Venetoclax University of Colorado, Denver | Phase 1 | CC |
ft538 Masonic Cancer Center, University of Minnesota | Phase 1 | D |
Same molecule, other indications
LISPRO-PH20 COMPONENT RHUPH20 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →